7151 - 7160 of 8587 Results
Title
Year
- The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II2022OPENTitle: The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and IIJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.994114Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.994114/pdfCitation Count: 4
- Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis2022OPENTitle: Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysisJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.927573Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.927573/pdfCitation Count: 3
- OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE2022OPENTitle: OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBEJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.914486Best OA location URL: https://doi.org/10.3389/fneur.2022.914486Citation Count: 7
- Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis2022OPENTitle: Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosisJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.919778Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.919778/pdfCitation Count: 9
- Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia2022OPENTitle: Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesiaJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.846126Best OA location URL: https://doi.org/10.3389/fneur.2022.846126Citation Count: 5
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study2022OPENTitle: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.773999Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/pdfCitation Count: 10
- The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program2022OPENTitle: The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development programJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.1036068Best OA location URL: https://doi.org/10.3389/fneur.2022.1036068Citation Count: 19
- Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease2022OPENTitle: Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's DiseaseJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.889647Best OA location URL: https://doi.org/10.3389/fneur.2022.889647Citation Count: 38
- Trends in the Utilization of Teleneurology and Other Healthcare Resources Prior to and During the COVID-19 Pandemic in an Urban, Tertiary Health System2022OPENTitle: Trends in the Utilization of Teleneurology and Other Healthcare Resources Prior to and During the COVID-19 Pandemic in an Urban, Tertiary Health SystemJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.834708Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.834708/pdfCitation Count: 9
- Editorial: Cannabinoids in neuroinflammation, neurodegeneration and pain: Focus on non-neuronal cells2022OPENTitle: Editorial: Cannabinoids in neuroinflammation, neurodegeneration and pain: Focus on non-neuronal cellsJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1114775Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1114775/pdfCitation Count: 1